- Home
- BEATW vs HNW Comparison
BEATW vs HNW Comparison
Compare BEATW & HNW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEATW
- HNW
- Stock Information
- Founded
- BEATW 2015
- HNW 2007
- Country
- BEATW United States
- HNW United States
- Employees
- BEATW N/A
- HNW N/A
- Industry
- BEATW Retail: Computer Software & Peripheral Equipment
- HNW Finance/Investors Services
- Sector
- BEATW Technology
- HNW Finance
- Exchange
- BEATW Nasdaq
- HNW Nasdaq
- Market Cap
- BEATW N/A
- HNW N/A
- IPO Year
- BEATW N/A
- HNW N/A
- Fundamental
- Price
- BEATW $0.57
- HNW $12.00
- Analyst Decision
- BEATW
- HNW
- Analyst Count
- BEATW 0
- HNW 0
- Target Price
- BEATW N/A
- HNW N/A
- AVG Volume (30 Days)
- BEATW 4.7K
- HNW 25.7K
- Earning Date
- BEATW 03-14-2025
- HNW 01-01-0001
- Dividend Yield
- BEATW N/A
- HNW 9.21%
- EPS Growth
- BEATW N/A
- HNW N/A
- EPS
- BEATW N/A
- HNW 1.19
- Revenue
- BEATW N/A
- HNW N/A
- Revenue This Year
- BEATW N/A
- HNW N/A
- Revenue Next Year
- BEATW N/A
- HNW N/A
- P/E Ratio
- BEATW N/A
- HNW $9.85
- Revenue Growth
- BEATW N/A
- HNW N/A
- 52 Week Low
- BEATW $0.50
- HNW $9.80
- 52 Week High
- BEATW $0.62
- HNW $11.76
- Technical
- Relative Strength Index (RSI)
- BEATW N/A
- HNW 51.27
- Support Level
- BEATW N/A
- HNW $11.96
- Resistance Level
- BEATW N/A
- HNW $12.13
- Average True Range (ATR)
- BEATW 0.00
- HNW 0.07
- MACD
- BEATW 0.00
- HNW 0.01
- Stochastic Oscillator
- BEATW 0.00
- HNW 56.45
About BEATW Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.